New drug combo shows promise against blood cancer in japanese trial
NCT ID NCT04661007
First seen Jan 05, 2026 · Last updated Jun 17, 2026 · Updated 25 times
Summary
This study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants have either relapsed/refractory or newly diagnosed disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aichi Cancer Center Hospital
Aichi, 464 8681, Japan
-
Chiba Cancer Center
Chiba, 260-8717, Japan
-
Iuhw Narita Hospital
Narita, 286-8520, Japan
-
Japanese Red Cross Nagoya Daini Hospital
Nagoya, 466-8650, Japan
-
Kanagawa Cancer Center
Yokohama, 241-8515, Japan
-
Kindai University Hospital
Sayama, 589-8511, Japan
-
Kobe City Medical Center General Hospital
Hyōgo, 650-0047, Japan
-
Kyushu University Hospital
Fukuoka, Japan
-
Mie University Hospital
Tsu, 514-0001, Japan
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
-
Nho Disaster Medical Center
Tachikawa, 190-0014, Japan
-
Nho Hokkaido Cancer Center
Sapporo, 003-0804, Japan
-
Nho Kumamoto Medical Center
Kumamoto-ken, 860-008, Japan
-
Nho Okayama Medical Center
Okayama, 701-1192, Japan
-
Nho Shikoku Cancer Center
Matsuyama, 791-0280, Japan
-
Osaka University Hospital
Suita-shi, 565-0871, Japan
-
Saitama Medical Center
Saitama-shi, 330-8503, Japan
-
The Cancer Institute Hospital of Jfcr
Kōtoku, 135-8550, Japan
-
Tohoku University Hospital
Miyagi, 980-8574, Japan
-
Tokai University Hospital
Kanagawa, 259-1193, Japan
-
University of Fukui Hospital
Fukui, 910-1193, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.